The Duke Division of Hematological Malignancies and Cellular Therapy pioneers the very latest and most promising approaches to bone marrow and stem cell transplantation.
Close collaboration between scientists and clinicians gives patients early access to many of these treatments, which is of special importance to patients with refractory or recurrent malignancies.
These new approaches include:
Projects include development of new therapies and study of the mechanisms behind graft-versus-host disease.
Learn more about our basic research.
Duke has shown that partially matched cord blood or haplo-identical stem cells can enable most patients (not just those with a matched sibling) to benefit from transplantation.
Learn more about our clinical research.
Collaborative research is a benchmark of the Duke Division of Hematological Malignancies and Cellular Therapy's research program.